Ann: Proposed issue of securities - CYP, page-24

"You also have also ironically posted, not what you purport as good objective scientific study, but an article on two employees of a company, Catalent Cell & Gene Therapy, pumping their company's ability to control said risks, and not good scientific evidence demonstrated with rigour, just a couple of biased company employees promoting their company."

Well perhaps you have at least now admitted that there is a risk, that is an open minded start for a change.

Maybe though you are correct and these 2 pretenders below have no idea.

Featured experts:

Dr Boris Greber is the Head of R&D for iPSC at Catalent Cell & Gene Therapy in Europe. He joined Catalent through the acquisition of RheinCell Therapeutics. Prior to this, Greber was an independent research group leader at the Max Planck Institute for Molecular Biomedicine in Germany. With over 15 years of expertise in basic and applied human iPSC research, he is internationally renowned for his pioneering contributions to the field.

Dr Frederic Cedrone is the Vice President of Corporate Innovation at Catalent, where he works closely with the Cell and Gene Therapy teams to drive innovation in emerging therapeutic modalities through strategic partnerships, licensing and technology acquisitions. Cedrone joined Catalent in 2022, bringing with him 18 years of experience in biotech, including key roles at Lysogene SA and Cellectis SA. His areas of expertise include biologic drug development, cell and gene therapies, and gene editing. Cedrone holds a PhD in molecular biology and enzyme engineering from Marseille University, France.